Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01529502 · ClinicalTrials.gov registry record · Phase 2

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

A Phase 2 study, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 2
Development phase
14
Enrollment target

NCT01529502: Completed Phase 2 study, sponsored by Massachusetts General Hospital.

NCT01529502 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01529502, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 2
Development phase
14 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether storage time affects how human body responds to autologous blood transfusion. An autologous blood transfusion is when a person donates blood and then receives that same blood back in the transfusion. We also want to find out if in this situation inhaled nitric oxide can help to prevent the potential reduction of vasodilation capacity. Vasodilation capacity is the ability of the blood vessel to widen when needed.

Interventions

  • PROCEDURE Red blood Cells auto-transfusion
  • DRUG Inhaled Nitric Oxide (iNO) administration

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2012-03
Est. Completion 2013-12
Phase Phase 2

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01529502

The ClinicalTrials.gov registry entry for NCT01529502 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Red blood Cells auto-transfusion is the first listed.

NCT01529502 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01529502 about?

NCT01529502 is a clinical study titled "Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting". The purpose of this study is to determine whether storage time affects how human body responds to autologous blood transfusion. An autologous blood transfusion is when a person donates blood and then receives that same blood back in the transfusion. We also want to find out if in this situation inha...

What is the current status of trial NCT01529502?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2012-03. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01529502?

The interventions under investigation include: Red blood Cells auto-transfusion (PROCEDURE), Inhaled Nitric Oxide (iNO) administration (DRUG).

Who is sponsoring clinical trial NCT01529502?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.